JP2020532958A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532958A5 JP2020532958A5 JP2020507679A JP2020507679A JP2020532958A5 JP 2020532958 A5 JP2020532958 A5 JP 2020532958A5 JP 2020507679 A JP2020507679 A JP 2020507679A JP 2020507679 A JP2020507679 A JP 2020507679A JP 2020532958 A5 JP2020532958 A5 JP 2020532958A5
- Authority
- JP
- Japan
- Prior art keywords
- ribonucleic acid
- acid compound
- cell
- compound according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762544220P | 2017-08-11 | 2017-08-11 | |
| US62/544,220 | 2017-08-11 | ||
| US201862671604P | 2018-05-15 | 2018-05-15 | |
| US62/671,604 | 2018-05-15 | ||
| PCT/US2018/046343 WO2019033051A1 (en) | 2017-08-11 | 2018-08-10 | RNA APTAMERS AGAINST THE TRANSFERRIN RECEPTOR (TFR) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020532958A JP2020532958A (ja) | 2020-11-19 |
| JP2020532958A5 true JP2020532958A5 (https=) | 2021-09-16 |
| JP7382919B2 JP7382919B2 (ja) | 2023-11-17 |
Family
ID=65271776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507679A Active JP7382919B2 (ja) | 2017-08-11 | 2018-08-10 | トランスフェリン受容体（ＴｆＲ）に対するＲＮＡアプタマー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11427826B2 (https=) |
| EP (1) | EP3664814A4 (https=) |
| JP (1) | JP7382919B2 (https=) |
| KR (1) | KR20200068647A (https=) |
| CN (2) | CN118931907A (https=) |
| AU (1) | AU2018314236B2 (https=) |
| CA (1) | CA3072575A1 (https=) |
| WO (1) | WO2019033051A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3953473A1 (en) * | 2019-04-12 | 2022-02-16 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| WO2020245198A1 (en) | 2019-06-04 | 2020-12-10 | Apterna Limited | APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR) |
| GB202019692D0 (en) | 2020-12-14 | 2021-01-27 | Apterna Ltd | Aptamer-sirna fusions |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| WO2026011165A1 (en) * | 2024-07-03 | 2026-01-08 | Creyon Bio, Inc. | Transferrin receptor (tfr) aptamers and use thereof |
| CN118879700B (zh) * | 2024-07-18 | 2025-11-07 | 四川大学 | 具有sirt1基因靶向激活功能的框架核酸药物的制备及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6344321B1 (en) * | 1990-06-11 | 2002-02-05 | Gilead Sciences, Inc. | Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met |
| US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| JP2008501621A (ja) | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 |
| JP2006089471A (ja) | 2004-08-26 | 2006-04-06 | National Institute Of Advanced Industrial & Technology | 癌の治療における抗モータリン２抗体と機能性核酸の使用 |
| CN101309703A (zh) | 2005-09-12 | 2008-11-19 | 诺维莫尼公司 | 抗cd3抗体组合物 |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| RS53008B2 (sr) | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| RU2769948C2 (ru) | 2007-04-03 | 2022-04-11 | Эмджен Рисерч (Мьюник) Гмбх | CD3-Эпсилон-связывающий домен с межвидовой специфичностью |
| JP5142265B2 (ja) | 2007-05-28 | 2013-02-13 | 独立行政法人産業技術総合研究所 | 抗モータリン抗体のパラトープ及びエピトープ |
| WO2011071099A1 (ja) | 2009-12-10 | 2011-06-16 | 独立行政法人産業技術総合研究所 | 抗癌性抗モータリンペプチド抗体 |
| WO2012046085A2 (en) * | 2010-10-08 | 2012-04-12 | Mina Therapeutics Limited | Methods of inducing insulin production |
| EP2836501B1 (en) | 2012-04-10 | 2018-03-07 | City of Hope | Rna aptamers for therapeutic and diagnostic delivery to pancreatic cancer cells |
| WO2014122143A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | Method for the selection of antibodies against bcma |
| CN105358693A (zh) | 2013-03-18 | 2016-02-24 | 约翰内斯堡威特沃特斯兰德大学 | Cd7受体适配体 |
| EP2789630A1 (en) | 2013-04-09 | 2014-10-15 | EngMab AG | Bispecific antibodies against CD3e and ROR1 |
| WO2014170063A1 (en) | 2013-04-19 | 2014-10-23 | Covagen Ag | Novel bispecific binding molecules with antitumoral activity |
| RU2016132863A (ru) | 2014-01-15 | 2018-02-20 | Займворкс Инк. | БИСПЕЦИФИЧЕСКИЕ CD3 и CD19 АНТИГЕНСВЯЗЫВАЮЩИЕ КОНСТРУКЦИИ |
| US9605266B2 (en) | 2014-07-16 | 2017-03-28 | City Of Hope | Cell-specific internalizing RNA aptamers against human CCR5 and uses therefore |
| KR20170055474A (ko) | 2014-07-31 | 2017-05-19 | 아카데미아 시니카 | 길항 pd-1 압타머 및 암 요법 관련 적용에서의 그의 적용 |
| CN107106697B (zh) | 2014-10-15 | 2021-06-18 | 希望之城 | Pdgfr rna适体 |
| WO2016061386A1 (en) | 2014-10-15 | 2016-04-21 | City Of Hope | Rna aptamers against transferrin receptor (tfr) |
| WO2016120325A1 (en) | 2015-01-27 | 2016-08-04 | Klinikum Rechts Der Isar Der Technischen Universität München | Quantitative assay for heat shock protein 70 (hsp70) protein in body fluids |
| US10577610B2 (en) | 2015-02-11 | 2020-03-03 | Deakin University | EpCAM aptamers and conjugates thereof |
| US10550394B2 (en) | 2015-03-31 | 2020-02-04 | City Of Hope | Anti-cancer RNA aptamers |
| US11219635B2 (en) | 2016-02-19 | 2022-01-11 | City Of Hope | Bi-specific aptamer |
| US20200181264A1 (en) | 2017-08-11 | 2020-06-11 | City Of Hope | Bispecific antigen-binding molecule |
-
2018
- 2018-08-10 KR KR1020207006810A patent/KR20200068647A/ko not_active Ceased
- 2018-08-10 WO PCT/US2018/046343 patent/WO2019033051A1/en not_active Ceased
- 2018-08-10 US US16/637,679 patent/US11427826B2/en active Active
- 2018-08-10 JP JP2020507679A patent/JP7382919B2/ja active Active
- 2018-08-10 AU AU2018314236A patent/AU2018314236B2/en not_active Expired - Fee Related
- 2018-08-10 CN CN202410700060.8A patent/CN118931907A/zh active Pending
- 2018-08-10 CA CA3072575A patent/CA3072575A1/en active Pending
- 2018-08-10 EP EP18844104.2A patent/EP3664814A4/en active Pending
- 2018-08-10 CN CN201880066428.2A patent/CN111542326B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532958A5 (https=) | ||
| Zhang et al. | The growth of siRNA-based therapeutics: Updated clinical studies | |
| JP6579629B2 (ja) | 筋障害を相殺するための手段と方法 | |
| US12071626B2 (en) | Splice-switching oligonucleotides and methods of use | |
| US11976092B2 (en) | RNA nanostructures, methods of making, and uses thereof | |
| JP7291418B2 (ja) | Ｐｃｓｋ９を標的としたアンチセンス核酸 | |
| US20220143197A1 (en) | siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer | |
| TW201919655A (zh) | 治療肌肉萎縮症的方法 | |
| AU2019219473B2 (en) | Skin-permeating carrier containing nucleic acid complex and use thereof | |
| US9050373B2 (en) | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same | |
| JP2022508609A5 (https=) | ||
| Karande et al. | Novel approaches for the delivery of biologics to the central nervous system | |
| JP2023526328A5 (https=) | ||
| US20220372493A1 (en) | Rna nanoparticle for liver cancer treatment | |
| KR20260005402A (ko) | 암 치료를 위한 조성물 및 방법 | |
| CN112567037B (zh) | 治疗或诊断tnf相关炎性疾病的tnf靶向适配体及其用途 | |
| JP2024063189A (ja) | 血液脳関門透過能を有するペプチド核酸複合体及びこれを含む組成物 | |
| Alkufi et al. | Delivery of nose to brain in the management of cerebral vasospasm in aneurysmal subarachnoid hemorrhage | |
| Liaw et al. | Assessment of the Oral Delivery of a Myelin Basic Protein Gene Promoter with Antiapoptotic bcl-xL (pMBP-bcl-xL) DNA by Cyclic Peptide Nanotubes with Two Aspect Ratios and Its Biodistribution in the Brain and Spinal Cord | |
| US20250367319A1 (en) | Targeted Nanomedicine for Treating Fibrotic Lung Disorders | |
| WO2023245177A2 (en) | Targeted nanomedicine for treating lung disorders | |
| WO2024077073A1 (en) | Cationic biomaterials ameliorate obesity-associated chronic inflammation and focal adiposity | |
| Liao | Zhilin Wu1, Chen Chen1Ε, Jiajia Luo1, Jacques RJ Davis1, Bo Zhang2, Liang Tang2, Wei Shi2 & | |
| HK40068943A (en) | Peptide-nucleic acid complex having blood-brain barrier penetration ability and composition comprising same | |
| JP2010518036A (ja) | アポリポタンパク質による血液脳関門を介しての薬剤の輸送 |